AR122644A1 - NEW CONJUGATED NUCLEIC ACID MOLECULES AND THEIR USES - Google Patents

NEW CONJUGATED NUCLEIC ACID MOLECULES AND THEIR USES

Info

Publication number
AR122644A1
AR122644A1 ARP210101648A ARP210101648A AR122644A1 AR 122644 A1 AR122644 A1 AR 122644A1 AR P210101648 A ARP210101648 A AR P210101648A AR P210101648 A ARP210101648 A AR P210101648A AR 122644 A1 AR122644 A1 AR 122644A1
Authority
AR
Argentina
Prior art keywords
integer
nucleic acid
independently
molecule
double
Prior art date
Application number
ARP210101648A
Other languages
Spanish (es)
Inventor
Christelle Zandanel
Original Assignee
Onxeo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onxeo filed Critical Onxeo
Publication of AR122644A1 publication Critical patent/AR122644A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Abstract

La presente invención se refiere a nuevas moléculas de ácido nucleico de interés terapéutico, en particular para uso en el tratamiento del cáncer. Reivindicación 1: Una molécula de ácido nucleico conjugado que comprende un resto de ácido nucleico bicatenario de 16 pares de bases, estando el extremo 5’ de la primera hebra y el extremo 3’ de la hebra complementaria unidos por un bucle; teniendo el resto de ácido nucleico bicatenario la siguiente secuencia SEQ ID Nº 1 de fórmula (1) en donde los enlaces internucleotídicos “s” se refieren a enlaces internucleotídicos de fosforotioato, y en donde los nucleótidos subrayados son nucleótidos modificados en 2’; siendo el bucle -O-P(X)OH-O-{[(CH₂)₂-O]ᵍ-P(X)OH-O}ʳ-K-O-P(X)OH-O-{[(CH₂)₂-O]ₕ-P(X)OHO-}ₛ- (I) siendo r y s independientemente un número entero 0 ó 1; g y h son independientemente un número entero de 1 a 7 y la suma g + h es de 4 a 7; siendo X O ó S; siendo K un resto de fórmula (2) con y, j, k y l independientemente un número entero de 0 a 6, preferentemente de 1 a 3; o O-P(X)OH-O-[(CH₂)ᵈ-C(O)-NH]ᵇ-CHR-[C(O)-NH-(CH₂)ₑ]ᶜ-O-P(X)OH-O- (II) siendo b y c independientemente un número entero de 0 a 4, y la suma b + c es de 3 a 7; siendo d y e independientemente un número entero de 1 a 3, preferentemente de 1 a 2; y siendo R -Lᶠ-J, siendo X O ó S, siendo L un enlazador y siendo f un número entero que es 0 ó 1, y siendo J una molécula que facilita la endocitosis o que es H. Reivindicación 2: La molécula de ácido nucleico conjugado según la reivindicación 1, en donde la molécula que facilita la endocitosis se selecciona del grupo que consiste en un colesterol, ácidos grasos de cadena simple o doble, ligando que se dirige a un receptor celular que permite la endocitosis mediada por receptor, o una transferrina.The present invention relates to new nucleic acid molecules of therapeutic interest, in particular for use in the treatment of cancer. Claim 1: A conjugated nucleic acid molecule comprising a 16 base pair double-stranded nucleic acid moiety, the 5 end of the first strand and the 3 end of the complementary strand being joined by a loop; the double-stranded nucleic acid moiety having the following sequence SEQ ID NO: 1 of formula (1) wherein "s" internucleotide linkages refer to phosphorothioate internucleotide linkages, and wherein the underlined nucleotides are 2-modified nucleotides; the loop being -O-P(X)OH-O-{[(CH₂)₂-O]ᵍ-P(X)OH-O}ʳ-K-O-P(X)OH-O-{[(CH₂)₂-O] ₕ-P(X)OHO-}ₛ- (I) where r and s are independently an integer 0 or 1; g and h are independently an integer from 1 to 7 and the sum g + h is from 4 to 7; being X O or S; K being a moiety of formula (2) with y, j, k and l independently an integer from 0 to 6, preferably from 1 to 3; or O-P(X)OH-O-[(CH₂)ᵈ-C(O)-NH]ᵇ-CHR-[C(O)-NH-(CH₂)ₑ]ᶜ-O-P(X)OH-O- ( II) where b and c are independently an integer from 0 to 4, and the sum b + c is from 3 to 7; d and e being independently an integer from 1 to 3, preferably from 1 to 2; and R being -Lᶠ-J, X being O or S, L being a linker and f being an integer that is 0 or 1, and J being a molecule that facilitates endocytosis or that is H. Claim 2: The acid molecule conjugated nucleic according to claim 1, wherein the molecule that facilitates endocytosis is selected from the group consisting of cholesterol, single or double chain fatty acids, ligand that targets a cellular receptor that allows receptor-mediated endocytosis, or a transferrin.

ARP210101648A 2020-06-19 2021-06-17 NEW CONJUGATED NUCLEIC ACID MOLECULES AND THEIR USES AR122644A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20305669 2020-06-19

Publications (1)

Publication Number Publication Date
AR122644A1 true AR122644A1 (en) 2022-09-28

Family

ID=71728679

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101648A AR122644A1 (en) 2020-06-19 2021-06-17 NEW CONJUGATED NUCLEIC ACID MOLECULES AND THEIR USES

Country Status (3)

Country Link
AR (1) AR122644A1 (en)
TW (1) TW202214857A (en)
WO (1) WO2021255223A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023220744A2 (en) * 2022-05-13 2023-11-16 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
ATE427948T1 (en) 2001-04-24 2009-04-15 Purdue Research Foundation FOLATE MIMETICS AND THEIR FOLATE RECEPTOR-BINDING CONJUGATES
ATE481985T1 (en) 2002-07-03 2010-10-15 Ono Pharmaceutical Co IMMUNOPOTENTATING COMPOSITIONS
US7488802B2 (en) 2002-12-23 2009-02-10 Wyeth Antibodies against PD-1
EP1639013B1 (en) 2003-07-02 2012-09-12 Innate Pharma Pan-kir2dl NK-receptor antibodies and their use in diagnostic and therapy
EP2292264A3 (en) 2003-07-24 2012-12-19 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
EP1526177A1 (en) 2003-10-24 2005-04-27 Institut Curie Nucleic acids useful for triggering tumor cell lethality
US7476729B2 (en) 2003-10-24 2009-01-13 Institut Curie Dbait and uses thereof
WO2007040469A2 (en) 2005-09-15 2007-04-12 Kosak Ken M Chloroquine coupled compositions and methods for their synthesis
PL1836225T3 (en) 2005-01-06 2012-05-31 Novo Nordisk As Kir-binding agents and methods of use thereof
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
EP1907424B1 (en) 2005-07-01 2015-07-29 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1934260B1 (en) 2005-10-14 2017-05-17 Innate Pharma Compositions and methods for treating proliferative disorders
MX2009001207A (en) 2006-08-18 2009-02-11 Hoffmann La Roche Polyconjugates for in vivo delivery of polynucleotides.
CN105037549B (en) 2007-01-11 2018-09-28 诺和诺德公司 Anti-KIR antibodies, preparation and its application
EP1944369A1 (en) 2007-01-12 2008-07-16 The Centre National de la Recherche Scientifique Dbait and its standalone uses thereof
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PL2170959T3 (en) 2007-06-18 2014-03-31 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
CA3102704A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
RU2531758C2 (en) 2008-02-11 2014-10-27 Куретек Лтд. Monoclonal antibodies for tumour treatment
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CA2721183C (en) 2008-04-11 2019-07-16 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
US20110223188A1 (en) 2008-08-25 2011-09-15 Solomon Langermann Targeted costimulatory polypeptides and methods of use to treat cancer
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
KR101814408B1 (en) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
WO2010065939A1 (en) 2008-12-05 2010-06-10 Indiana University Research & Technology Corporation Combination therapy to enhace nk cell mediated cytotoxicty
EP2376105B1 (en) 2008-12-18 2015-07-29 Dana-Farber Cancer Institute, Inc. Nkg2d-fc for immunotherapy
SI3279215T1 (en) 2009-11-24 2020-07-31 Medimmune Limited Targeted binding agents against b7-h1
JP2013512251A (en) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Simultaneous inhibition of PD-L1 / PD-L2
US8993731B2 (en) 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
KR101846590B1 (en) 2010-06-11 2018-04-09 교와 핫꼬 기린 가부시키가이샤 Anti-tim-3 antibody
JP2013532153A (en) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Bispecific antibodies against TIM-3 and PD-1 for immunotherapy against chronic immune disease
EA032867B9 (en) 2010-06-22 2020-01-22 Онксео Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012071411A2 (en) 2010-11-22 2012-05-31 Innate Pharma Sa Nk cell modulating treatments and methods for treatment of hematological malignancies
KR101970025B1 (en) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Antibodies and other molecules that bind b7-h1 and pd-1
SG195082A1 (en) 2011-05-25 2013-12-30 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory disorders
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
DK2785375T3 (en) 2011-11-28 2020-10-12 Merck Patent Gmbh ANTI-PD-L1 ANTIBODIES AND USES THEREOF
EP3553086A1 (en) 2012-05-31 2019-10-16 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
US9845356B2 (en) 2012-08-03 2017-12-19 Dana-Farber Cancer Institute, Inc. Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
PL2904011T3 (en) 2012-10-02 2018-01-31 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
MX370848B (en) 2012-10-04 2020-01-08 Dana Farber Cancer Inst Inc Human monoclonal anti-pd-l1 antibodies and methods of use.
AR093984A1 (en) 2012-12-21 2015-07-01 Merck Sharp & Dohme ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
SI2970464T1 (en) 2013-03-15 2020-08-31 Glaxosmithkline Intellectual Propety Development Limited Anti-lag-3 binding proteins
US10851148B2 (en) 2013-03-15 2020-12-01 Novelogics Biotechnology, Inc. Antibodies to MICA and MICB proteins
WO2014170441A1 (en) * 2013-04-19 2014-10-23 Dna Therapeutics Inhibition of dna damage repair by artificial activation of parp with oligonucleotide molecules
WO2014179664A2 (en) 2013-05-02 2014-11-06 Anaptysbio, Inc. Antibodies directed against programmed death-1 (pd-1)
CN111423511B (en) 2013-05-31 2024-02-23 索伦托药业有限公司 Antigen binding proteins that bind to PD-1
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
MX2016003292A (en) 2013-09-13 2016-06-24 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics.
CA2926856A1 (en) 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
WO2015081158A1 (en) 2013-11-26 2015-06-04 Bristol-Myers Squibb Company Method of treating hiv by disrupting pd-1/pd-l1 signaling
SI3081576T1 (en) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN113637692A (en) 2014-01-15 2021-11-12 卡德门企业有限公司 Immunomodulator
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
JP2017505773A (en) 2014-01-28 2017-02-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Anti-LAG-3 antibody for treating hematological malignancies
US9885721B2 (en) 2014-05-29 2018-02-06 Spring Bioscience Corporation PD-L1 antibodies and uses thereof
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
JP6526189B2 (en) 2014-07-03 2019-06-05 ベイジーン リミテッド Anti-PD-L1 antibodies and their use for therapy and diagnosis
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
MY193661A (en) 2014-11-06 2022-10-24 Hoffmann La Roche Anti-tim3 antibodies and methods of use
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
AR103867A1 (en) 2015-03-06 2017-06-07 Sorrento Therapeutics Inc ANTIBODIES AGAINST IMMUNOGLOBULIN AND DOMAIN 3 CONTAINING MUCINE OF T-CELLS (ANTI-TIM3), USEFUL AS THERAPEUTIC AGENTS
MA41867A (en) 2015-04-01 2018-02-06 Anaptysbio Inc T-CELL IMMUNOGLOBULIN AND MUCINE PROTEIN 3 ANTIBODIES (TIM-3)
PL3325623T6 (en) 2015-07-23 2022-05-30 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
US10815290B2 (en) 2015-11-10 2020-10-27 Fred Hutchinson Cancer Research Center NKG2D decoys
WO2017083612A1 (en) 2015-11-13 2017-05-18 Dana-Farber Cancer Institute, Inc. An nkg2d-ig fusion protein for cancer immunotherapy
EP3374389A1 (en) 2015-11-13 2018-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
CA3016355A1 (en) 2016-03-01 2017-09-08 Onxeo Treatment of cancer by systemic administration of dbait molecules
CN108779178A (en) 2016-03-15 2018-11-09 依奈特制药公司 Anti- MICA antibody
WO2018035330A1 (en) 2016-08-19 2018-02-22 Janssen Biotech, Inc. Methods of treating crohn's disease with an anti-nkg2d antibody
AU2017344411A1 (en) 2016-10-19 2019-05-09 Novelogics Biotechnology, Inc. Antibodies to MICA and MICB proteins
WO2018148447A1 (en) 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
US20200407720A1 (en) 2018-03-13 2020-12-31 Onxeo A dbait molecule against acquired resistance in the treatment of cancer

Also Published As

Publication number Publication date
TW202214857A (en) 2022-04-16
WO2021255223A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
Saarbach et al. Peptide nucleic acid (PNA) and its applications in chemical biology, diagnostics, and therapeutics
Koppelhus et al. Cellular delivery of peptide nucleic acid (PNA)
US20220401467A1 (en) Oligonucleotides, compositions and methods thereof
JP6629712B2 (en) Nucleic acid molecules that induce RNA interference with intracellular penetration ability and uses thereof
Gissot et al. Nucleoside, nucleotide and oligonucleotide based amphiphiles: a successful marriage of nucleic acids with lipids
JP5296328B2 (en) Single-stranded circular RNA and method for producing the same
ES2689696T3 (en) Retinoid liposomes to enhance the modulation of hsp47 expression
JP2013531981A (en) Method for selective oligonucleotide modification
US20140140929A1 (en) Chemically modified cell-penetrating peptides for improved delivery of gene modulating compounds
ES2926369T3 (en) Single-stranded nucleic acid molecule that has a delivery function and ability to control gene expression
CZ14395A3 (en) Hybrid oligonucleotic phosphorothioates
JPH06506834A (en) Closed antisense and sense oligonucleotides and their applications
MXPA06002660A (en) Modified oligonucleotides for telomerase inhibition.
WO2006119619A1 (en) Oligonucleotides inhibiting cell proliferation
CN104726458A (en) Lipid-modified Double-stranded Rna Having Potent Rna Interference Effect
US20090317906A1 (en) Gene silencing using sense dna and antisense rna hybrid constructs coupled to peptides facilitating the uptake into cells
AR122644A1 (en) NEW CONJUGATED NUCLEIC ACID MOLECULES AND THEIR USES
Govan et al. Cellular delivery and photochemical activation of antisense agents through a nucleobase caging strategy
US11390867B2 (en) G-quadruplex-containing antisense oligonucleotides
RU2020117611A (en) OLIGONUCLEOTIDE STRUCTURES AND THEIR APPLICATION
Ugarte-Uribe et al. Synthesis, cell-surface binding, and cellular uptake of fluorescently labeled glucose− DNA conjugates with different carbohydrate presentation
US9803198B2 (en) Lipohillic oligonucleotide analogs
Sanchez et al. Conjugation reactions involving maleimides and phosphorothioate oligonucleotides
AU776114B2 (en) Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
Biscans et al. Synthesis, binding, nuclease resistance and cellular uptake properties of 2′-O-acetalester-modified oligonucleotides containing cationic groups

Legal Events

Date Code Title Description
FB Suspension of granting procedure